BARDA issues RFP for anthrax antitoxins

The Biomedical Advanced Research and Development Authority has requested that researchers develop anthrax antitoxin products for the treatment of symptomatic anthrax disease resulting from Bacillus anthracis spores being released into the air.

The request for proposals calls for the manufacture and delivery of the anthrax antitoxin to the Strategic National Stockpile that could be used in humans as a U.S. Food and Drug Administration-approved product or during a declared emergency, Global Biodefense reports.

"Although much progress has been made on anthrax (medical countermeasure) preparedness over the past ten years, it is critical to continue development, manufacturing, and acquisition of MCMs for anthrax," the RFP said. "In order to maintain a capability to respond to an anthrax attack, the (U.S. government) needs to continue investment in the manufacturing, testing, and delivery of new doses of anthrax antitoxins."

The contract also requires that proposals include the development and maintenance of master cell banks so that monoclonal antibody anthrax antitoxins can be produced. In addition, the contract requires the collection and storage of human immune plasma so that polyclonal anthrax antitoxins may be manufactured.

The RFP is in support of a Department of Health and Human Services plan to acquire and store medical countermeasures to mitigate injuries and illnesses caused by biological threat agent, physical radiologic, chemical and nuclear exposures, according to Global Biodefense.

Multiple proposals may be awarded indefinite delivery, indefinite quantity contracts with a base period of up to five years or 60 months. The proposal deadline is July 30.